Acute Vulvovaginal Candidiasis Treatment; Depends on the Severity and Frequency of the Infection

 

Acute Vulvovaginal Candidiasis Treatment

Acute vulvovaginal candidiasis is a yeast infection, which affects the vagina and tissues present at the opening of the vulva. Candidiasis is a fungal infection caused by yeast (type of fungus) called Candida, which is present in the human body. While, vulvovaginal candidiasis refers to the vaginal and vulval symptoms caused by Candida albicans. Candidiasis in the vagina is commonly called a vulvovaginal candidiasis or vaginal yeast infection. Symptoms of vulvovaginal candidiasis include external dysuria, dyspareunia, pruritus, vaginal soreness, and abnormal vaginal discharge.

Acute vulvovaginal candidiasis is commonly observed in women in the reproductive age group. It is quite uncommon in prepubertal and/or postmenopausal females. It can cause intense itchiness, inflammation, and a thick, white discharge from a vagina. Fluconazole, clotrimazole, and nystatin are some of the most commonly used drugs for the acute vulvovaginal candidiasis treatment. Apart from these, other drugs such as Terconazole, Terbinafine, Ketoconazole, and Miconazole are also available in the market for the acute vulvovaginal candidiasis treatment.

The global acute vulvovaginal candidiasis treatment is estimated to be valued at US$ 308.0 Mn in 2020 and is expected to exhibit a CAGR of 3.0% over the forecast period (2020-2027).

Vulvovaginal candidiasis is usually treated with antifungal medication. The oral triterpenoid agent, ibrexafungerp, is the first non-azole antifungal approved (by U.S. Food and Drug Administration) for vulvovaginal candidiasis and the first drug approved in a new antifungal class for vulvovaginal candidiasis in more than 20 years. Some women with infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Taking antifungal drug for 3 to 7 days usually clear a yeast infection.

A variety of factors can make a woman more susceptible to Acute Vulvovaginal Candidiasis Treatment, such as estrogen, antibiotic use, a change in immune function, and a history of recurrent infections with Candida. Some studies show that the presence of yeasts in the vaginal mucosa, called a yeast layer, is a risk factor for development of VVC. Over-the-counter creams and suppositories are often used to treat this condition before seeking medical care. One should consult a doctor immediately to be evaluated for other causes of vulvovaginal candidiasis.

Acute vulvovaginal candidiasis is a condition that occurs in up to 3 out of 4 women at some point during their life and can be triggered by a variety of factors. The condition usually responds quickly to antifungal therapy and has a high rate of cure, although some women may develop recurrent vulvovaginal candidiasis (RVVC), which is defined as four or more episodes per year.